Almost three-quarters of patients with non-clear-cell renal cell carcinoma may benefit from treatment with the tyrosine kinase receptor inhibitor cabozantinib, suggesting its efficacy is not limited to clear-cell disease, say researchers.
Three trials point to the potential of regimens incorporating agents targeting the programmed cell death protein 1 or its ligand in patients with non-clear-cell renal cell carcinoma.
The phase III TIVO-3 trial has found that both progression-free survival and response are significantly better with tivozanib than sorafenib in patients with refractory metastatic renal cell carcinoma.
Overall survival is significantly improved with the first-line combination of pembrolizumab and axitinib relative to sunitinib in patients with advanced renal cell carcinoma, shows the KEYNOTE-426 trial.
Patients with previously untreated intermediate- or poor-risk advanced renal cell carcinoma derive greater health-related quality of life benefits from nivolumab plus ipilimumab than from sunitinib, CheckMate 214 data show.
Second-line treatment with vascular endothelial growth factor receptor–tyrosine kinase inhibitors after failure of nivolumab plus ipilimumab continues to benefit patients with metastatic renal cell carcinoma, report researchers.
Adjuvant treatment with sunitinib may be associated with an increased mortality risk for older female patients with renal cell carcinoma, suggests a post-hoc analysis of the ASSURE trial that compared sunitinib and sorafenib with placebo.
Taking proton pump inhibitors alongside tyrosine kinase inhibitors is associated with an increased mortality risk in older cancer patients, research indicates.
Adding the mutation status of three genes linked to renal cell carcinoma improves the prognostic value of the Memorial Sloan Kettering Cancer Center risk model for patients receiving tyrosine kinase inhibitors for metastatic disease, research shows.
Results of the JAVELIN Renal 101 trial indicate that patients with a new diagnosis of advanced renal cell carcinoma have better outcomes when treated with the combination of avelumab and axitinib than with sunitinib.
Germline mutations may be common in patients with advanced renal cell carcinoma and may have the potential to guide therapy if detected, US researchers report.
Patient-reported outcomes from the IMmotion151 study favor atezolizumab plus bevacizumab as a first-line regimen for the treatment of patients with metastatic clear cell renal cell carcinoma.
Results of the phase III CARMENA trial show that treatment with sunitinib alone is as good as treatment with nephrectomy followed by sunitinib in patients with intermediate- or poor-risk metastatic renal cell carcinoma.
Results from the JAVELIN Renal 100 study suggest that avelumab plus axitinib is a tolerable combination, with encouraging antitumor activity in treatment-naïve patients with advanced renal cell carcinoma.
Axitinib plus pembrolizumab can be tolerated and shows promising antitumor activity in patients with advanced renal cell carcinoma, researchers from an early-stage US trial say.